#United States #San Diego #Class Action #Robbins LLP #Vistagen

Vistagen Therapeutics, Inc. Class Action Overview

In recent news, Robbins LLP has brought to light a significant class action lawsuit concerning Vistagen Therapeutics, Inc. (NASDAQ: VTGN). This lawsuit has been initiated for the benefit of all investors who acquired Vistagen stock between April 1, 2024, and December 16, 2025. The clinical-stage biopharmaceutical firm specializes in developing treatments aimed at addressing neuropsychiatric and neurological disorders.

Background on the Legal Action

The class action stems from allegations claiming that Vistagen Therapeutics misled its investors about the validity of its clinical trial for its drug fasedienol, designed for the treatment of social anxiety disorder. Prior to the announcement of the class action, the company had shared overwhelmingly positive assessments pertaining to their clinical trial outcomes, suggesting that fasedienol would attain favorable results. However, evidence presented in the class action lawsuit contends that during this period, Vistagen concealed critical information about material adverse facts related to its Phase 3 PALISADE-3 study.

On December 17, 2025, following the conclusion of the trial, Vistagen made a shocking announcement. The company disclosed that the PALISADE-3 study failed to demonstrate a statistically significant improvement on its primary endpoint, leading to a stunning drop in the stock price. The share value plummeted from $4.36 before the announcement to as low as $0.86, a staggering decline of over 80%. This sharp decrease has prompted investors to scrutinize the company’s prior communication and actions.

Next Steps for Shareholders

Investors who purchased shares within the stated timeframe and who believe they have been impacted are encouraged to come forward and consider joining the class action. The law firm Robbins LLP is providing guidance for those interested in serving as the lead plaintiff in the lawsuit. It is crucial for potential lead plaintiffs to submit the required documentation to the court by March 16, 2026. The lead plaintiff is expected to act on behalf of all class members in directing the litigation process, though participation is not necessary to receive compensation.

If shareholders choose to remain inactive, they still qualify as absent class members, meaning they can opt to share in the lawsuit's potential recovery without needing to become actively involved. All representation in this case operates on a contingency fee basis, ensuring that shareholders are not charged any legal fees or expenses unless they receive restitution.

About Robbins LLP

Robbins LLP has an established reputation in the realm of shareholder rights litigation. Since its inception in 2002, the firm has dedicated itself to aiding investors in recovering financial losses, enhancing corporate governance, and holding corporate leaders accountable for misconduct. The firm's extensive experience in such matters makes it a valuable ally for Vistagen shareholders looking for recourse.

Interested parties can register for updates regarding the class action, which will notify them if a settlement is reached, or to receive alerts about future corporate wrongdoing. This vital information can assist shareholders in being informed and prepared as they navigate this complex situation.

Conclusion

As uncertainty looms over Vistagen Therapeutics and its shareholders post-trial outcomes, it is essential for impacted investors to remain vigilant and proactive. Engaging with Robbins LLP ensures that individuals are well-informed about their rights and the opportunities available for redress through this class action lawsuit. To take action or learn more, you can reach out to Robbins LLP directly at their designated contact channels.